The induction of the cell surface heparan sulfate proteoglycan syndecan-1 (Sdc1) in stromal fibroblasts is observed in more than 70% of human breast carcinomas. Using a coculture model, we have recently shown that stromal cell-derived Sdc1 stimulates carcinoma cell proliferation in vitro, and that this activity requires Sdc1 glycanation. In the present study, we investigated the effect of stromal cell Sdc1 on breast carcinoma growth in vivo. MDA-MB-231 human breast carcinoma cells were inoculated into the flanks of athymic nude mice either alone, or as mixed suspensions with Sdc1-transfected or mock-transfected 3T3 mouse fibroblasts. The mixed tumors showed an intimate association between carcinoma cells and stromal fibroblasts and histologically closely resembled poorly differentiated human breast carcinomas. The presence of fibroblasts led to significantly accelerated tumor growth, which was further augmented (88% increase) by forced expression of stromal Sdc1. The hyperemic macroscopic appearance of tumors containing Sdc1-positive stromal cells contrasted with pale tumors developing in the presence of mock-transfected fibroblasts, which prompted us to examine tumor microvessels. Stromal Sdc1 expression was associated with a significantly elevated microvessel density (36% increase) and a larger vessel area (153% increase). To evaluate the relevance of this finding in human breast cancer, the relationship between stromal Sdc1 and tumor vascularity was also examined in a tissue array containing 207 human breast carcinoma samples. Similar to the xenografts, stromal Sdc1 expression correlated with both vessel density (P ¼ 0.013) and total vessel area (P ¼ 0.0026). In conclusion, stromal fibroblast-derived Sdc1 stimulates breast carcinoma growth and angiogenesis in vivo.
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The syndecans represent a four-member family of transmembrane cell surface heparan sulfate proteoglycans (HSPGs). Their biologic effects on adhesion, migration and growth factor signaling are thought to be mediated through the binding of growth factors, including fibroblast growth factors (FGFs), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) or extracellular matrix (ECM) molecules via their heparan sulfate (HS) chains (Steinfeld et al., 1996; Bernfield et al., 1999) . Core protein-mediated interactions with integrins have also been reported (Beauvais and Rapraeger, 2003; Beauvais et al., 2004; Burbach et al., 2004) . Syndecan-1 (Sdc1), the beststudied member of this family, decorates the normal epithelia, but is also transiently expressed in condensing mesenchyme during embryonal morphogenesis (Vainio et al., 1989a, b; Solursh et al., 1990) . Aberrant Sdc1 expression in stromal fibroblasts has recently been described in infiltrating breast carcinomas, mimicking mesenchymal induction during development (Stanley et al., 1999; Maeda et al., 2004) .
Stromal Sdc1 induction is not unique to breast carcinomas as it is also seen in basal cell carcinoma, gastric carcinoma, thyroid carcinoma and head and neck squamous cell carcinoma (Bayer-Garner et al., 2000; Wiksten et al., 2001; Barbareschi et al., 2003; Ito et al., 2003; Mukunyadzi et al., 2003; Mennerich et al., 2004) . In some tumor types, stromal Sdc1 relates to poorer prognosis (Wiksten et al., 2001; Ito et al., 2003) . In myelomas, the stromal accumulation of Sdc1 extracellular domain shed from the tumor cells correlates with tumor cell growth (Bayer-Garner et al., 2001; Yang et al., 2002) .
To examine the role of Sdc1 in tumor stroma, we have previously characterized stromal Sdc1 expression in human and murine mammary tumor samples and developed an in vitro coculture model to simulate Sdc1 induction (Maeda et al., 2004) . This work has demonstrated that breast carcinoma cells induce Sdc1 in fibroblasts and that Sdc1-expressing fibroblasts reciprocally promote breast carcinoma cell growth. It was the purpose of the present study to examine the effect of stromal Sdc1 expression in vivo. Using mixed fibroblastcarcinoma cell xenografts, we find that Sdc1-expressing fibroblasts promote tumor growth and tumor angiogenesis. The significant correlation between stromal Sdc1 and blood vessel density was confirmed in human breast carcinoma tissue samples, which supports the clinical relevance of this link.
Sdc1 expression by stromal fibroblasts promotes carcinoma cell growth in vivo: We have previously simulated stromal Sdc1 induction in two-dimensional coculture and demonstrated that Sdc1 expression in fibroblasts promotes the growth of neighboring breast carcinoma cells in vitro (Maeda et al., 2004) . This observation prompted us to investigate stromal Sdc1 effects in a more physiologically relevant model. Mixed suspensions of MDA-MB-231 human mammary carcinoma cells and 3T3 fibroblasts, which were either transfected to overexpress Sdc1 (3T3/Sdc1) or transfected with empty vector (3T3/mock), were inoculated into athymic mice. Tumors produced by the MDA-MB-231 plus 3T3/mock fibroblast combination exhibited a faster growth rate compared with MDA-MB-231 cells alone (Figure 1a) . Tumor growth was further significantly accelerated when MDA-MB-231 carcinoma cells were combined with 3T3/Sdc1 fibroblasts instead of 3T3/mock cells (Figure 1a) . The significantly increased wet weight of MDA-MB-231 þ 3T3/Sdc1 tumors (82720 mg) compared to MDA-MB-231 þ 3T3/mock tumors (42724 mg, Po0.001) also reflected the differ- were either stained with H&E or immunostained with anti-human CK or anti-mouse Sdc1 antibody as indicated. Human carcinoma cells were identified with rabbit polyclonal anti-human pan-CK antibody NCL-Ckp (1:100 dilution; Novocastra, Newcastle, UK), using a protocol recommended by the manufacturer. The Envision Plus detection system (Dako, Carpinteria, CA, USA) with diaminobenzidene substrate was used for detection. A high proportion of carcinoma cells was seen in tumors containing either stromal cell type. For Sdc1 detection, epitope retrieval was performed by heating for 2 min in a pressure cooker in 0.01 M citrate buffer. After blocking, the sections were incubated with rat monoclonal antibody 281-2 against mouse Sdc1 ectodomain (Jalkanen et al., 1985) (4 mg/ml; gift from Dr AC Rapraeger). Alexa 568-conjugated goat anti-rat IgG (1:400 dilution; Molecular Probes, Eugene, OR, USA) served as secondary detection reagent. Mouse Sdc1 expression was detected in spindle-shaped cells, which represented an integral component of MDA-MB-231 þ 3T3/Sdc1 tumors. Original magnification, Â 200.
Stromal syndecan-1 promotes tumor growth and angiogenesis T Maeda et al ence in growth rates (Figure 1b) . Histologically, the 3T3 fibroblast-containing tumors resembled poorly differentiated human breast carcinomas and displayed a close relationship between polygonal carcinoma cells and spindly fibroblasts. On hematoxylin and eosin (H&E)-stained sections, there was no apparent difference between tumors containing 3T3/mock or 3T3/Sdc1 fibroblasts (Figure 2) . MDA-MB-231 carcinoma cells identified by cytokeratin (CK) immunolabeling were abundant in tumors containing either stromal cell type (Figure 2 ). Murine Sdc1 was strongly expressed in the stromal cells of MDA-MB-231 þ 3T3/Sdc1 tumors (Figure 2 ). In the MDA-MB-231 þ 3T3/mock tumors, low levels of stromal Sdc1 were also seen, suggesting that some Sdc1 induction does occur in 3T3/mock fibroblasts in vivo.
Sdc1 expression by stromal fibroblasts stimulates angiogenesis in human breast carcinoma xenografts: Ample experimental evidence supports the notion that the vascularization of tumors is a key regulator of tumor growth. In fact, the degree of angiogenesis may be a crucial growth rate-limiting determinant, which defines the tumor growth 'ceiling' (Sund et al., 2005) . Tumor angiogenesis is thought to be regulated by the relative balance of pro-and antiangiogenic cues from tumor cells and the tumor microenvironment. Macroscopically, the MDA-MB-231 þ 3T3/mock tumors appeared pale at day 20 compared to the MDA-MB-231 þ 3T3/ Sdc1 tumors, suggesting improved blood supply in the tumors containing Sdc1-expressing fibroblasts (not shown). To examine potential differences in tumor vessels, we labeled tissue sections with an antibody to the endothelial marker CD31 (PECAM). The average vessel density was significantly higher (Po0.001) in MDA-231 þ 3T3/Sdc1 tumors (34.273.9 vessels per Â 600 field) compared to MDA-231 þ 3T3/mock tumors (25.273.6 vessels per Â 600 field) (Figure 3a and b). The difference in total vessel area was even more pronounced, indicating that the blood vessels were also larger in tumors with Sdc1-positive stroma (Po0.001) Figure 4 Stromal Sdc1 expression correlates with the vascular area in human breast carcinomas. A tissue array was constructed from 207 archival breast carcinoma samples. (a) Tissue array slides were immunolabeled with an antibody to Sdc1 as described (Mundhenke et al., 2002) and the staining intensity was evaluated manually on a scale of 0 (negative) to 3 (strong staining). Original magnification, Â 200. Abbreviations: 'Ca' ¼ carcinoma, 'S' ¼ stroma. (b) Slides from the same array were also labeled with an antibody to the endothelial marker vWF using a rabbit polyclonal antibody (DAKO, Carpinteria, CA, USA). Original magnification, Â 200. vWF-positive blood vessels were identified and analysed with respect to the number and relative surface area, using ImageJ software v1.32j (NIH, public domain). Lower and upper thresholds of the 8-bit images were set at '0' and '25', respectively. Particles were analysed (minimum size: 50 pixels; maximum size: 600 pixels; bins: 20), resulting in a vessel count and total vessel area. Figure 3c ). This result suggests a proangiogenic effect of stromal Sdc1. Stromal Sdc1 expression correlates with vascularization in human breast carcinomas: To test the clinical relevance of this finding, we examined the relationship between stromal Sdc1 expression and tumor vessels in human breast carcinoma tissue samples. Slides from a tissue array, which contains samples from 207 breast carcinomas, were immunolabeled with antibodies to Sdc1 and the endothelial marker von Willebrand factor (vWF) (Figure 4a and b) . Similar to the tumor xenografts, expression of Sdc1 in stromal fibroblasts correlated significantly with vessel density (P ¼ 0.013) and with the average vessel area (P ¼ 0.0026), using computerized image analysis and the nonparametric Spearman rank correlation test (Figure 4c and d) . Overall, these observations support the hypothesis that the aberrant expression of Sdc1 in carcinoma-associated fibroblasts stimulates tumor angiogenesis.
Known functions of Sdc1 provide attractive hypotheses to explain the tumorigenic effects of this molecule. A multitude of mitogens, including FGFs, HGF and heparin-binding EGF-like growth factor (HB-EGF), require HS chains for signaling (Bernfield et al., 1999; Derksen et al., 2002) . This is best documented for the FGF family members, where HS participates in a ternary active signaling complex with the growth factor ligand and the receptor tyrosine kinase (Schlessinger et al., 2000) . Indeed, FGF receptor (FGFR) activation by heterotypic cell-cell contacts has been described in vitro (Richard et al., 1995; Filla et al., 1998) , and in situ signaling complex reconstitution assays indicate that breast carcinoma stroma HSPGs can promote binding of FGF2 to FGFR1 (Friedl et al., 2001; Maeda et al., 2004) . Stroma-derived Sdc1 may also compete with carcinoma cell Sdc1 for binding with integrin adhesion receptors, which would likely modulate matrix interactions and consequently growth (Beauvais and Rapraeger, 2003; Beauvais et al., 2004; Burbach et al., 2004) . The fact that HS promotes signaling of both FGF2 and VEGF, which represent the two most potent known proangiogenic factors, provides a molecular basis for the observed stimulation of tumor angiogenesis by Sdc1-rich stroma (Tessler et al., 1994) .
In summary, Sdc1 induction in reactive stromal fibroblasts creates a favorable microenvironment for accelerated tumor cell growth and angiogenesis. Thus, this cell surface HSPG joins a group of molecules, which are aberrantly expressed in the stromal compartment and contribute to carcinoma progression.
